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Depending upon viral genotype, productive papillomavirus infection and disease display preferential
tropism for cutaneous or mucosal stratiﬁed squamous epithelia, although the mechanisms are unclear.
To investigate papillomavirus entry tropism, we used reporter pseudovirions based on various
cutaneous and mucosal papillomavirus species, including the recently identiﬁed murine papilloma-
virus. Pseudovirus transduction of BALB/c mice was examined using an improved murine skin infection
protocol and a previously developed cervicovaginal challenge model. In the skin, HPV5, HPV6, HPV16,
BPV1 and MusPV1 pseudovirions preferentially transduced keratinocytes at sites of trauma, similar to
the genital tract. Skin infection, visualized by in vivo imaging using a luciferase reporter gene, peaked
between days 2–3 and rapidly diminished for all pseudovirion types. Murine cutaneous and genital
tissues were similarily permissive for pseudovirions of HPV types 5, 6, 8, 16, 18, 26, 44, 45, 51, 58 and
animal papillomaviruses BPV1 and MusPV1, implying that papillomavirus’ tissue and host tropism is
governed primarily by post-entry regulatory events in the mouse.
Published by Elsevier Inc.Introduction
Papillomaviruses (PV) comprise a group of small, non-
enveloped DNA viruses that infect humans and many other
vertebrate species. To date, more than 180 genotypes have been
characterized and classiﬁed into 29 genera (Bernard et al., 2010),
based on the nucleotide sequence relatedness of the PV major
capsid protein L1. Productive infection and induction of neoplasia
is species-speciﬁc and PVs that affect humans (HPV) are clustered
in ﬁve of these genera, namely alpha, beta, gamma, mu and nu.
Additionally, HPVs can be designated as either a cutaneous or
mucosal type based on the preferential productive lesion/papil-
loma formation in stratiﬁed squamous epithelia of skin or
mucosa, respectively. However, these designations represent
infection preferences, rather than absolute requirements for
infection of a speciﬁc anatomical area. For example, HPV 2, a
common cause of verrucae vulgares on the skin, can also be
detected in benign vulvar warts of children (Aguilera-Barrantes
et al., 2007) and in oral lesions (de Villiers, 1989). HPV 8, which is
responsible for the development of non-melanoma skin cancer inInc.
).Epidermodysplasia verruciformis patients and possibly in non-
genetically predisposed individuals (Gewirtzman et al., 2008), has
been detected in some oropharyngeal tumors (Lindel et al., 2009).
Conversely, mucosal HPVs can also infect skin sites. High-risk
mucosal HPV types were detected in digital Bowen’s diseases and
squamous cell cancers (SCC), some of these in association with
concomitant or antecedent genital malignancies (Forslund et al.,
2000; Kreuter et al., 2009). High-risk mucosal HPV 26 has been
detected in a few cervical carcinomas, but recently has more often
been found in SCC of the ﬁngers and toes of individuals infected
with HIV-1 (High et al., 2003; Kreuter et al., 2005; Handisurya
et al., 2007).
Tissue tropism cannot be explained solely by the phylogeny of
PV types. For instance, the mucosal HPV types 6 and 11, which
share 85% sequence identity within their L1 genes, show differ-
ences in their predilection for speciﬁc sites. HPV 6 is more
commonly found in anogenital warts than HPV 11, while HPV
11 is found more frequently in laryngeal papillomas. The closely
related type HPV 13, which has 78% sequence identity to both
HPV 6 and 11, causes focal epithelial hyperplasia of the oral cavity
and has not been detected in either anogenital or laryngeal
papillomas (Syrjanen, 2003). HPV 7 and 40, sharing 87% L1
nucleotide sequence identity, also affect different anatomical
sites. HPV 7 is responsible for Butcher’s warts, particularly on
Table 1
Ratio of reporter plasmid copies vs. infectious units or L1 capsids.
Pseudovirion
types
Reporter plasmid copies/
infectious units (mean7SD)
Capsid equivalents/
reporter plasmid
HPV 5 481172249 4.70
HPV 6 73721 5.51
HPV 8 6357777 1.35
HPV 16 67726 3.78
HPV 18 171716 1.47
HPV 26 53734 4.41
HPV 44 360713 3.36
HPV 45 23733 1.33
HPV 51 116728 1.14
HPV 58 37762 2.50
Mus PV 28715 2.54
BPV 1 174756 1.34
A. Handisurya et al. / Virology 433 (2012) 385–394386the hands of meat handlers, while HPV 40 causes mucosal
papillomas of the anogenital and laryngeal tract. It is important
to note that infection is often identiﬁed as a clinically apparent
lesion, so apparent tropism may often correspond to sites at
which papillomatous changes can be induced, with the possibility
that sites of asymptomatic infection remain underappreciated.
The reasons for the observed tissue tropism are unclear,
despite several attempts to clarify the factors responsible for
preferential PV infection and/or induced neoplasia at speciﬁc
sites. Characterization of the genetic elements that control tissue
tropism has suggested that the long control (LCR) or upstream
regulatory region serve to inﬂuence the tropism of HPV types
(Steinberg et al., 1989). This region contains enhancer elements
that show some tissue or cell type speciﬁcity and likely play a role
in the initial expression of the viral genes after virus infection
(Howley and Lowy, 2007). Differences in the capacity of tran-
scriptional activation have been shown for the LCR of cutaneous
HPV 5 and mucosal HPV 16, using cell lines of different deriva-
tions (Mistry et al., 2007). Furthermore, prediction of transcrip-
tion factor binding sites revealed that, while some binding sites
are present in all LCRs, e.g., AP-1, other binding sites are restricted
to certain genera or even HPV types (Garcı´a-Vallve´ et al., 2006).
These differences in the LCR may singly, or in combination, have
an impact on the preferential infection of distinct types of
epithelia by the individual PV genotype.
Another factor in the determination of tissue tropism could be
the interaction of the PV capsid proteins with host attachment
factors. In vivo, attachment to negatively charged heparan sulfate
proteoglycans (HSPG) on the basement membrane (BM) is
regarded as the initial step leading to infection, at least for types
examined until now: HPV 5, HPV 16, HPV 31 and HPV 45 (Johnson
et al., 2009; Schiller et al., 2010). After undergoing a conforma-
tional change followed by furin cleavage of the L2 minor capsid
protein, the L1 major capsid protein is thought to bind to a still
undetermined secondary receptor on the cell surface, leading to
internalization of the virus (Kines et al., 2009). It has been
suggested that differences in the surface charge of PV L1 proteins
may inﬂuence viral attachment, and modeling of the net surface
charges has suggested that cutaneous HPV exclusively display
negatively charged L1 surfaces, whereas positively charged L1
surfaces were predominantly modeled for mucosal alpha-PV
(Mistry et al., 2008). Whether these hypothetical differences
affect infectious entry tropism in vivo is unclear. HSPGs do show
great variability across individual cell types, due to differences in
sulfation patterns and other chemical modiﬁcations of the
heparan sulfate side chains, which are the target of initial PV
binding (Turnbull et al., 2001). This heterogeneity might theore-
tically skew the binding of virions towards cells or the BM of
cutaneous and/or mucosal origins. However, it is important to
note that HSPGs are invariably negatively charged and would
therefore be expected to interact with positively charged peptides
on the virion surface.
To investigate whether the tissue speciﬁcity of cutaneous and
mucosal PV types is determined at the level of infectious entry,
from BM binding through establishment of the genome in the
nucleus to initiate transcription, we have determined the in vivo
infectivity of PV pseudovirions (PsV) concomitantly at a cuta-
neous and a mucosal site. Cutaneous exposure was achieved
using an improved murine model for skin infection and mucosal
exposure employed a previously published cervicovaginal chal-
lenge model of PV transmission (Roberts et al., 2007). The use
of PsV allowed the delivery of an identical reporter plasmid
(pseudogenome), thereby eliminating the potential confounding
variability in gene expression for native PV genomes. Addition-
ally, PsV infection can be readily and repeatedly quantiﬁed in vivo
in an animal over an extended time course, using luciferase geneexpression as a marker of infection. We included PsV of the
recently identiﬁed mouse papillomavirus, Mus PV 1 (Ingle et al.,
2011), to assess the possibility that infection tropism or kinetics
might be inﬂuenced by a natural host versus a heterologous host
species.Results
PsV preparations of different PV types have variable particle to
infectivity ratios in vitro
PsV representative of cutaneous (HPV 5, 8), low- (HPV 6, 44) and
high-risk mucosal HPV types (HPV 16, 18, 26, 45, 51, 58), and two
animal PV, bovine PV type 1 (BPV 1) and the recently identiﬁed
murine PV, Mus PV 1, were generated by encapsidation of the
reporter plasmid pCLucf, which contains a luciferase expression
cassette (Johnson et al., 2009). In addition to luciferase, this reporter
plasmid also expresses enhanced green ﬂuorescent protein (GFP),
which means the in vitro infectivity of PsV carrying pCLucf can be
monitored by ﬂow cytometric measurement of GFP expressing cells
or luciferase. To evaluate the relative infectivity of cutaneous and
mucosal PV types, the amount of encapsidated pCLucf reporter
plasmid for various PsV stocks was calculated by quantitative PCR
(qPCR) and compared to the GFP-transducing potential of the stock
on a per cell basis of 293TT cells in vitro. Surprisingly, the observed
particle to infectivity ratios were highly variable for different PV types
(Table 1). The lowest mean ratios of 23, 37, 53 and 28 (i.e., most
potent per particle infectivity) were observed for the high-risk
mucosal HPV types 45, 58 and 26 and the new murine PV, Mus PV 1,
respectively. The highest mean ratio of 4811 was obtained with
preparations of cutaneous HPV 5. The ratios were similar among
different preparations of the same PsV type (Table 1). The slight
variabilities observed are likely due to minor differences in the
passage number or physiological state of the producing cell line
293TT at time of PsV production. No correlation between the
calculated ratios and the genera or tissue tropism of the PVs was
evident. Furthermore, because empty capsids might compete with
the transduction of the pseudogenome, we also determined the
number of L1 capsids per encapsidated pCLucf reporter plasmid.
The range of the calculated ratios was between 1.14 and 5.51 present
in the stock. No correlation was observed between reporter plasmid
encapsidation efﬁciency and infectivity (Table 1).
An improved murine skin challenge model allows efﬁcient and
consistent infection with PV PsV
We next established an efﬁcient and reliable method for
infection of murine skin that could be used to compare the
Fig. 1. In vivo imaging of BALB/c mice three days after skin challenge. A luciferase
expression plasmid was packaged into pseudovirions composed of the capsid
proteins of the new mouse papillomavirus Mus PV 1. Mice were challenged
cutaneously with a pseudovirus inoculum containing 1109 copies of luciferase
reporter plasmid (pseudogenome), as determined by qPCR. (A) Imaging of mice
prior to and (B) 10 min after intraperitoneal administration of 100 ml luciferin
substrate (15 mg/ml). Control mice received phosphate-buffered saline instead of
pseudovirus. Imaging of control mice was performed (C) prior to and (D) after
substrate administration. All images were taken in the IVIS 100 imaging system
using medium binning and 60 s exposure and analyzed with the Living Image
3.0 software. The color scales represent the average radiance given in p/s/cm2/sr.
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and cervicovaginal tract. PsV encapsidating the luciferase reporter
plasmid pCLucf were employed in all experiments to enable
readout by in vivo imaging analysis, as this method allows
sequential in situ quantitative assessment of infection in the same
living animal. An essential feature of the recently developed
murine model for cervicovaginal infection of PsV (Roberts et al.,
2007) was the deliberate disruption of the vaginal epithelium, as
intact epithelia were found to be resistant to PV infection.
However, deliberate disruption was not used in the previously
reported skin challenge model (Gambhira et al., 2007; Alphs et al.,
2008). We found that skin disruption with a hand rotary device
with an attached felt wheel followed by pipette delivery of PsV
solutions and scoring the liquid into the pre-scariﬁed area
allowed for efﬁcient and reproducible infection. This procedure
was more consistent and robust than the previously reported
method of applying the PsV to freshly shaved skin (Gambhira
et al., 2007; Alphs et al., 2008). Repeated evaluations for consis-
tency of our new method using identical amounts of the same PsV
preparation (e.g., corresponding to 1109 reporter plasmid
copies in Mus PV 1 PsV) over a time period of 6 months in 15
animals from different animal batches and of different ages gave
similar luminescence signals in all animals, with average radiance
values ranging from 2.1104 to 2.5105 p/s/cm2/sr (mean
average radiance 8.3104 p/s/cm2/sr). This improved abrasive
technique with the hand rotary device enabled directed and
evenly distributed removal of the epidermis layer by layer until
the BM was exposed and evolved as a fast and easy method for
testing large numbers of mice. To initiate infection, PsV solutions
were delivered onto the pre-scariﬁed area by pipette delivery and
scored into the skin. Similar to the cottontail rabbit PV (CRPV)
model (Cladel et al., 2008), inoculation with PsV three days after
scariﬁcation gave the most consistent results, whereas inocula-
tion immediately after scariﬁcation proved inefﬁcient. For exam-
ple, when 1109 of Mus PV 1 reporter were used, inoculation
performed immediately after scariﬁcation resulted in lumines-
cence signals, that, if positive at all, were almost two logs lower
compared to inoculation performed three days after scariﬁcation
using the same stock and amount of PsV (e.g., mean 1.4103 p/s/
cm2/sr versus mean 7.7104 p/s/cm2/sr, respectively).
Fig. 1 shows visualization of murine skin infection three days
after PsV inoculation. Imaging of mice prior to intraperitoneal
administration of the substrate luciferin consistently revealed no
luminescence signal (Fig. 1A and C). On the third day after
inoculation with 1109 copies of pCLucf pseudogenome, a
positive signal was readily detected as soon as 3 min after
luciferin administration. The luminescent signal strength steadily
rose until reaching a plateau at 15–20 min (data not shown).
Fig. 1B shows in vivo imaging of mice using PsV based on the
recently identiﬁed Mus PV 1 (Ingle et al., 2011) 10 min after
administration of luciferin. Luminescence signals of control mice
that had received phosphate-buffered saline (PBS) instead of PsV
preparations remained undetectable at any timepoint after sub-
strate administration (Fig. 1D).
PsV of diverse origin infect murine epidermal keratinocytes
To determine the cellular distribution of PsV infection in skin,
mice were simultaneously challenged with PsV preparations
encapsidating either the reporter plasmid pCLucf or pNaMB. The
use of the luciferase plasmid facilitated precise excision of the
inoculated area by luminometric imaging immediately prior to
necropsy. The pNaMB plasmid, encoding a ‘‘tailless’’ non-signaling
fragment of human CD4, enabled detection and localization of the
infected cells within the biopsied material by immunoﬂuorescent
staining and confocal microscopy. Human CD4 was selected as amarker for PsV infection because of its distinctive cell surface
localization and the availability of reliable commercial antibodies
suitable for its detection by immunohistochemistry. Efforts to
microscopically detect the expressed luciferase protein did not
yield consistent and satisfactory results.
Fig. 2 shows immunoﬂuorescent confocal microscopy analyses
of murine skin three days after challenge with representatives of
human and animal PsV. HPV 5 (Fig. 2A) and HPV 16 (Fig. 2B) were
chosen as representatives of cutaneous and mucosal HPV types,
respectively. Mus PV 1 (Fig. 2C and F) was chosen because it
represents a PV for which the mouse is the natural host, while
BPV 1 (Fig. 2D) represents an animal PV for which the mouse is a
heterologous host. Co-staining for CD49f (integrin alpha-6), which
is highly expressed in basal keratinocytes especially along the
basal aspect of these cells (Stepp et al., 1990), was concomitantly
detected to enable localization of PsV infected cells relative to
these cells. For every PV type investigated, virally-infected cells
were distributed within the epithelium of the skin overlying the
BM. As expected, CD4 expression was clearly associated with the
cell surface of cells with keratinocytic morphology. No differences
in the pattern of infected cells were noted among the individual
PsV types. Skin tissue sections from mice mock-infected with PBS
served as controls to determine speciﬁcity (Fig. 2E). These tissues
Fig. 2. Cellular distribution of pseudogenome expression for representatives of different human and animal papillomavirus types in the (A)–(E) skin and in (F) genital
tissues, visualized by immunoﬂuorescent staining and confocal microscopy. All pseudovirions encapsidated the reporter gene plasmid pNaMB, which encodes a non-
signaling ‘‘tailless’’ human CD4 reporter gene. Detection was performed using an antibody speciﬁc for human CD4 followed by Alexa Fluor 488-conjugated secondary
antibody (green). To determine the localization of infected cells in relation to the basement membrane, co-staining was performed with an anti-CD49f (integrin alpha 6)
phycoerythrin-labeled antibody (red). Skin samples (A)–(E) were analyzed on day three, genital tissues (F) on day two after infection. The representatives of human and
animal papillomaviruses are as follows: (A) cutaneous HPV 5; (B) mucosal HPV 16; (C), (F) mouse papillomavirus and (D) bovine papillomavirus 1. (E) Skin tissues of
control mice that were mock-treated with phosphate-buffered saline.
A. Handisurya et al. / Virology 433 (2012) 385–394388lacked speciﬁc staining with anti-human CD4, but readily showed
staining of the basal keratinocytes with anti-CD49f. Staining of
murine vaginal tissues infected with Mus PV 1 PsV (Fig. 2F)
revealed staining of epithelial cells in a distribution similar to PsV
of other PV types as reported previously (Roberts et al., 2007),
demonstrating that Mus PV 1 PsV are able to infect vaginal
tissues. Vaginal tracts of mice that received PBS again served as
speciﬁcity controls and did not reveal anti-CD4 staining (data not
shown).Skin infection peaks at day 2–3 for cutaneous and mucosal types
To determine the dynamics of skin infection, in vivo imaging
analysis was employed in mice challenged with PsV of various PV
types, each expressing 1109 copies of the luciferase-reporter
plasmid. Luminescence was measured each day for a total of 10
days. At each timepoint, luminescence was measured prior to
administration of the substrate to ensure that there were no residual
signals from the preceding day. The time course of in vivo skin
Fig. 3. Dynamics of luciferase expression for representatives of human and animal papillomaviruses. Skin challenge was performed with luciferase-harbouring
pseudovirions, corresponding to a total of 1109 luciferase pseudogenome copies per inoculation. Readout was performed by in vivo imaging analysis daily for ten
consecutive days. Control mice received phosphate-buffered saline instead of pseudovirions. The substrate luciferin was administered by intraperitoneal injection. Each
experimental group consisted of ﬁve animals and results of the average radiance are given in mean p/s/cm2/sr7standard deviation.
A. Handisurya et al. / Virology 433 (2012) 385–394 389infection of representative PsV types, HPV 5, HPV 6, HPV 16, BPV
1 and Mus PV 1, are shown in Fig. 3. For all PsV types investigated,
luminescence signals were detectable one day after infection, showed
a sharp increase in intensity until a peak on either day 2 or day 3, and
rapidly declined thereafter. A notable exception to this pattern was
that Mus PV 1 reproducibly exhibited a slower decline in signal,
dropping to below 5% of maximum value only after seven days. For
all PsV types tested, the luminescence signals remained undetectable
after they returned to background levels.
PsV of cutaneous and mucosal human and animal PV types similarily
infect murine tissues of cutaneous and mucosal–genital origin
We next compared the efﬁciency of cutaneous versus mucosal
infectivity of different PsV types. To ensure comparability ofin vivo infectivity, PsV preparations of the different PV types,
each containing 1109 luciferase reporter plasmid copies, were
used as above for each inoculation, and the same mouse was
concomitantly infected at both the skin on the back and the
cervicovaginal tract. The luciferin substrate was delivered by
intraperitoneal administration to allow similar distribution of
the substrate to the two sites within the same mouse. Lumines-
cence was detected on day 2 and 3 after infection, based on the
previously determined maxima in luminescence signals for the
skin and the reported peak for cervicovaginal tissues (Roberts
et al., 2007; Day et al., 2010). Fig. 4 shows representatives of
cutaneous and mucosal low- and high-risk HPV types as well as
the two animal PV types.
Genital luminescence tended to be higher on day 2 than day 3,
whereas the opposite was true for skin sites. However, HPV 5 and 8,
Fig. 4. Comparison of the efﬁciency of different pseudovirions in infection of murine skin and cervicovaginal tissues. Mice were concomitantly challenged on the skin of
the back and in the cervicovaginal tract with pseudovirions carrying an encapsidated luciferase-expressing pseudogenome. The amount for each inoculation corresponded
to 1109 pseudogenomes, as determined by qPCR. Mice that had been mock-infected with phosphate-buffered saline served as controls. Readout was performed after
intraperitoneal administration of the luciferin substrate by in vivo imaging analysis on days two and three post infection. Each experimental group consisted of ﬁve animals
and results of the average radiance are given in mean p/s/cm2/sr7standard deviation.
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cervicovaginal tissues and exhibited higher levels at day 2 at both
sites (data shown for HPV 5). The luminescent intensity for HPV 6, a
representative of low-risk mucosal HPV, was initially higher in the
genital tract compared to the cutaneous site, by day three the
luminescence signal peaked for the skin, whereas the signal hadsharply declined in the cervicovaginal tract. Therefore, despite
differences in the kinetics of infection, the overall infectivity of
both tissues was approximately equal. The low-risk mucosal HPV
44 behaved similarly to HPV 6 (data not shown).
PsV of several high-risk mucosal HPV types were generated
and studied, including HPV 16, 18, 26, 45, 51, and 58. Two trends
A. Handisurya et al. / Virology 433 (2012) 385–394 391emerged from this analysis. For HPV types 16, 18, and 45, overall
infectivity appeared to be equal between the infected tissue types,
similar to the results observed with low-risk mucosal HPV.
However, HPV 26, 51 and 58 (data for HPV 51 and 58 not shown)
exhibited somewhat greater infection of the skin on day 2 as well
as on day 3, compared to genital tissues. However, these differ-
ences were not signiﬁcant.
PsV of representative animal PV, Mus PV 1 and BPV 1, similarly
revealed slight superiority in the efﬁciency of cutaneous infection
compared to cervicovaginal infection. On a per pseudogenome
basis, Mus PV 1 was one of the more efﬁcient PsV at infecting the
mouse skin and vaginal tract, but not more efﬁcient than HPV 26.
Thus, it does not appear that species-restricted interactions play a
major role in early events of PV infection.Discussion
In this study, we use PV pseudovirus technology to address the
entry tropism of different PV types in the mouse. Although our
previous studies had demonstrated infection of the cervicovaginal
tissue with HPV 5, a cutaneous type, this infection was substan-
tially weaker than that of HPV 16 and HPV 31 shown in the same
study (Johnson et al., 2009). Therefore, we considered the possi-
bility that some measure of tropism could be determined at the
level of initial capsid interaction with the BM or viral entry into
target keratinocytes.
Results from the murine model for cervicovaginal infection
(Roberts et al., 2007) showed that disruption of the epithelium,
which allows access and binding of the virions to the BM, appears
to be necessary for initiation of PV infection of the cervicovaginal
tract in vivo. To establish an improved model for murine skin
infection, several methods of physical and/or chemical cutaneous
disruption were assessed. These included ‘‘tape-stripping’’, abra-
sion with sandpaper, scariﬁcation with razor blades, placement of
a microneedle patch, pre-hydration of skin with water or ethanol
to induce swelling of the keratinocytes, or application of Non-
oxynol-9, the non-ionic membrane-active surfactant that is used
to disrupt the epithelium in the cervicovaginal challenge model.
In our hands, scariﬁcation with a hand rotary device with an
attached felt wheel emerged as the most consistent, robust and
reproducible method for in vivo infection of murine skin, resulting
in substantially higher luminescence signals compared to other
methods tested (data not shown). For example, compared to the
second best method of skin disruption, manual scariﬁcation using
a razor blade, abrasion with the hand rotary device resulted in
one log higher luminescence signals, as determined by side-by-
side comparison using the same amount and stock of PsV, and
was less traumatic for the animals.
Employing this improved model of cutaneous challenge, we
found that skin and mucosal tissues are both susceptible to in vivo
infection by PsV of different cutaneous and mucosal PV types and
species. No major differences were observed in the overall
efﬁciency of infection among different human and animal PsV
types. With all analyzed types, the infected keratinocytes within
the epithelium were observed in a linear array, highly suggestive
that infected keratinocytes migrated from the basal layers
towards the surface during the differentiation process. No indica-
tion of infection of other cell types was observed in either skin or
genital sites for any of the PV types examined.
Although subtle differences in the kinetics of PsV infection of
skin and of genital tissues were observed, the biological relevance
of this observation is unclear. It is more plausible that these
differences are attributable to the methods of infection. For
cervicovaginal infection, inoculation with PsV was performed four
hours after chemical disruption of the epithelium with theanionic detergent Nonoxynol-9. Histologic analysis revealed that
at that time point the genital epithelium is partially ablated,
allowing access of PsV to the BM. In the skin challenge model,
infection was initiated three days after physical disruption of the
epithelial layers. The resultant scab, present on the previously
scariﬁed area, overlying the denuded epithelium, may delay
diffusion of the PsV to the BM. Furthermore, in contrast to the
genital tract, inoculation performed immediately after scariﬁca-
tion did not result in reliable infection. It is conceivable that this is
due to the PsV inoculum becoming entangled in the vigorous
serum exudate that occurs immediately after skin abrasion and is
unable to efﬁciently reach the BM. Alternatively, perhaps the
induction of the scab after cutaneous wounding retards migration
of the keratinocytes over the exposed BM relative to their
migration rate in wounded cervicovaginal epithelium. Prolonged
exposure of the capsids on the BM before contacting the kerati-
nocytes might make them more susceptible to engulfment by
monocytes and neutrophils that would be expected to also
migrate into the sites of wounding. However, immunoﬂuorescent
staining of skin tissues three days after infection did not indicate
infection of cell types other than keratinocytes. If the PsV do
interact with phagocytic cells in this setting, it is likely that they
are routed down a degradative rather than an infectious pathway.
When comparing different PsV types within the skin model,
some differences in the kinetics of infection were observed.
Analysis of HPV 5 PsV revealed short-lasting expression with a
rapid decline, which became undetectable after only three days,
even on the skin, which is thought to be the ‘‘appropriate’’ target
site. In contrast, luminescence signals of high-risk mucosal HPV
16 were measurable for a period of up to six days, although the
peak signal was similar for the two PsV types (Fig. 3). This
difference in the duration of expression is puzzling, since the
same luciferase pseudogenome was transduced and no viral
genes were expressed. Perhaps infection is simply more asyn-
chronous for HPV 16.
The recently identiﬁed murine PV emerged as an interesting
new PV type. Mus PV 1 PsV showed a prolonged and very intense
expression after infection of the skin. Whether this characteristic
is due to factors involved in homologous infection or due to other
virus-speciﬁc factors remains unclear. Further investigation to
determine if this PV type is a superior vector for (trans)cutaneous
vaccination strategies is warranted. Another interesting trend was
observed with the high-risk mucosal types HPV 26 and HPV 58.
These types seem to more efﬁciently infect cutaneous tissues.
This observation is consistent with the ﬁnding that these types
are often detected in the skin of ﬁngers and toes of immunocom-
promised individuals. Why these types may be more amenable to
infection of cutaneous epithelia remains to be elucidated.
Although the same number of reporter plasmid copies was
used in all the in vivo experiments, the absolute numbers of
average radiance varied between the individual experiments. The
exact reasons for this observed phenomenon are difﬁcult to
decipher, but possible explanations include the fact that mice
used for different experiments varied in age and batch, variabil-
ities between readings with the IVIS on different days may have
occurred, and different PsV stocks were used in different experi-
ments. However, in vitro titration on 293TT cells was broadly
predictive for in vivo infectivity, although these cells are derived
from a multiply-transformed human embryonic kidney cell line,
that would appear to be of limited biological relevance to in vivo
PV infection.
As PsV-based studies are capable of addressing the early
events in the PV lifecycle, our results imply that differences in
the availability of viral receptors, endosome escape, or genome
trafﬁcking to the nucleus do not account for the species speciﬁcity
or preferential infection and neoplastic transformation of speciﬁc
A. Handisurya et al. / Virology 433 (2012) 385–394392anatomical sites by PV. Previous studies have demonstrated that PV
virus-like particles or native virions of BPV 1 can bind to a variety of
cultured cell lines derived from various organs and animal species,
implying a broad distribution of a PV receptor(s) involved in
attachment (Roden et al., 1994; Volpers et al., 1995; Mu¨ller et al.,
1995). However, the relevance of these observations to in vivo
infection is unclear, given the differences in early events of infection
in vitro and in vivo (Kines et al., 2009). Of more relevance, homo-
logous (CRPV capsid/CRPV genome) and chimeric (HPV 16 capsid/
CRPV genome) PV particles can successfully infect rabbit cutaneous
tissues (Mejia et al., 2006). However, this assay has only a limited
ability to quantify the extent of infection. The results described
herein provide the strongest support to date for the notion that
diverse PV types share common mechanisms for the early events of
infection in mucosal and squamous epithelia, implying that down-
stream post-entry events are responsible for the PV species and
tissue tropism. These may include qualitative and quantitative
differences in the replication capacity of the viral genomes of PV
types in cells of different origins or the availability of cellular factors
determining viral gene expression. Clearly, further investigations on
the post-entry molecular determinants are warranted to understand
PV tissue tropism.Methods
PsV production
PsV of cutaneous and mucosal HPV as well as animal PV were
produced according to the protocol published on the laboratory
website http://home.ccr.cancer.gov/Lco/ (Buck and Thompson, 2007).
Brieﬂy, 293TT cells, derived from a human embryonic kidney cell line
and modiﬁed to express high levels of SV40 Large T antigen, were co-
transfected with plasmid vectors expressing the PV major and minor
capsid proteins, together with a reporter gene plasmid. Assembled
particles encompassing the reporter gene were puriﬁed by Optiprep
gradient centrifugation.
Nucleotide maps of the plasmid vectors for the different PV
types, including the new murine PV, are available on the labora-
tory website. For generation of Mus PV 1 PsV, a bicistronic
mammalian expression plasmid encoding the L1 and L2 proteins
was created by synthetic codon-modiﬁcation of the capsid protein
open reading frames using a previously-reported algorithm
(Pastrana et al., 2004) also available on our laboratory website.
The major and minor capsid proteins of HPV types 8, 44, and 51
were codon-optimized (Kondo et al., 2009) and engineered into
the double expression vector pVITRO1-neo-mcs (InvivoGen).
The pNaMB reporter gene plasmid was generated by transfer-
ring a C-truncated human CD4 open reading frame from pMACS-
IRES-CD4 (Miltenyi Biotec Inc.) into pSU-5697 (Buck et al., 2004).
The pCLucf plasmid has been described previously (Johnson et al.,
2009). Nucleotide maps of the reporter gene vectors for human
CD4 (pNaMB) and luciferase (pCLucf) are posted on the laboratory
website.
293TT cells were maintained and grown in Dulbecco’s mod-
iﬁed Eagle’s medium supplemented with 10% fetal bovine serum.Characterization and quantiﬁcation of PsV preparations
Puriﬁed PsV preparations were characterized for their infec-
tivity, their amount of major capsid protein L1 and encapsidated
DNA, and for their reporter plasmid copy numbers.
Brieﬂy, infectious titers of puriﬁed PsV preparations were
determined by infecting 293TT cells with PsV containing pCLucf
and measuring the number of GFP-positive cells by ﬂowcytometric analysis 48 h after infection (Kines et al., 2009). Titers
are given in infectious units per milliliter (IU/ml).
The L1 content of the PsV preparations was quantiﬁed by
sodium-dodecyl sulfate-polyacrylamide gel electrophoresis of
puriﬁed PsV preparations followed by staining with SYPROs Ruby
(Molecular Probes, Life Technologies) according to the manufac-
turer’s protocol.
Encapsidated DNA contents of PsV preparations were deter-
mined by electrophoresis analysis on agarose gels after release of
DNA from the L1/L2 capsids by proteinase K treatment (Johnson
et al., 2009).
Reporter plasmid copy numbers were determined from encap-
sidated DNA, previously extracted from puriﬁed PsV preparations
(protocol available on the laboratory website). After extraction
DNA was subsequently analyzed by qPCR using the DyNAmoTM
SYBRs Green qPCR Kit (Thermo Fisher Scientiﬁc Inc.) according to
the manufacturer’s instructions using primers speciﬁc for GFP.
The sequences for primers for GFP are as follows: forward primer
50-GACTTCAAGGAGGACGGCAAC-30, reverse primer 50-GGTGTT
CTGCTGGTAGTGGTCG-30. The copy numbers were calculated
using known amounts of pCLucf plasmids as standards and the
ratio of reporter plasmid copy numbers to infectious units
determined.
The determination of the ratio of capsids per reporter plasmid
was made based on the calculation of 30,000 capsids per pg of L1,
and the ratio was normalized to 1109 reporter plasmid copies.
Murine models of cutaneous and cervicovaginal PsV infection
Female BALB/cAnNCr mice of 6–8 weeks of age were obtained
from the National Institutes of Health. Housing and handling were
performed in accordance with their guidelines and experimental
protocols were approved by the National Cancer Institute’s
Animal Care and Use Committee.
For cutaneous PsV infection, the dorsal hair of the mice was
removed three days prior to infection, ﬁrst using an electric
clipper followed by application of Nair (Church & Dwight Co.,
Inc.) depilatory cream for 20 s. In order to remove the uppermost
layers of the epidermis an area of 21.5 cm on the skin on the
back was carefully scariﬁed using a hand rotary device with an
attached felt wheel (Dremel 300 series). After three days, infec-
tion was performed by pipetting the PsV solution in a total
volume of 20 ml in PBS onto the previously scariﬁed site followed
by gently scoring the liquid into the skin using a 26 gauge 3/8’’
needle without removal of the scab.
Cervicovaginal infection was performed according to a pre-
viously published protocol (Roberts et al., 2007). Brieﬂy, mice
received progesterone (3 mg Depo-Provera dissolved in 100 ml
sterile PBS) subcutaneously on day 4 in order to potentiate
susceptibility for infection. On day 0 the genital mucosa was
disrupted by Nonoxynol-9 (Conceptrol, Mc Neil Pharmaceutical
Inc.) treatment four hours prior to instillation of the PsV solution
(total volume of 20 ml, dissolved in 4% carboxymethylcellulose
(CMC)) into the vaginal vault.
In vivo analysis of PsV infection
Determination of the luciferase activity in PV PsV-infected
tissues represents a standard readout for infectivity, and expres-
sion of luciferase activity was measured using an in vivo lumines-
cence imager. All PsV preparations were used in an amount of
1109 reporter plasmid copy numbers, as determined by qPCR,
for every infection regardless of tissue site. Readout was per-
formed on the indicated days post infection by intraperitoneal
injection of 100 ml of D-luciferin potassium salt (15 mg/ml, diluted
in Dulbecco’s modiﬁed Eagle’s medium) (Caliper Life Sciences)
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Life Sciences) 10 min after administration of the substrate with
medium binning and 60 s exposure. Images were analyzed and
the average radiance (given in p/s/cm2/sr) within the region of
interest was determined with the Living Image 3.0 software
(Caliper Life Sciences). Data are representative of ﬁve mice per
group, and experiments were performed in duplicate. Statistical
analysis was performed using the GraphPad Prism software.
Harvest of tissue samples
For immunoﬂuorescent imaging studies, mice were infected with
a mixture of PsV encapsidating either pCLucf or pNaMB according to
the established protocol for skin or cervicovaginal infection. For skin
specimens, imaging with IVIS 100 was performed three days post
infection after intraperitoneal administration of D-luciferin Potassium
Salt to facilitate retrieval of the exact localization of the previously
infected sites. Mice were then euthanized by CO2 inhalation and skin
necropsies were taken from the previously marked sites. To verify
proper removal, biopsies were read again in the IVIS 100 and positive
samples were subsequently snap frozen in Tissue-Tek OCT Compound
freezing medium (Sakura Finetek).
For processing of the genital tract specimens, the entire genital
vault was dissected after euthanization on day two post infection
and snap frozen in Tissue-Tek OCT Compound freezing medium.
All tissue samples were stored at 80 1C until further analysis.
Immunoﬂuorescent staining
Tissue sections were cut at 6 mm thickness, mounted on Super-
frost Plus Microscope Slides (Fisher Scientiﬁc) and ﬁxed by incubation
in 100% ethanol for 10min at 20 1C. Nonspeciﬁc binding sites were
blocked with 10% donkey serum (Jackson ImmunoResearch Labora-
tories Inc.) in PBS with 0.1% Brij 58 for 30 min at room temperature. A
rat monoclonal antibody recognizing human CD4 (LifeSpan BioS-
ciences Inc.) was used at a dilution of 1:200 and sections were
incubated for 1 h at 37 1C. Detection was perfomed with Alexa Fluor
488-conjugated donkey anti-rat secondary antibody (Invitrogen, Life
Technologies) diluted 1:1000. To visualize basal keratinocytes sec-
tions were co-stained with a phycoerythrin-labelled anti-CD49f anti-
body (integrin alpha 6, BD Pharmingen) for 1 h at 37 1C. Following
staining, sections were mounted with ProLongs Gold antifade
reagent containing DAPI (Molecular Probes, Life Technologies) to
visualize nuclei.
All microscopy analysis was performed on a Zeiss LSM 510 UV
system. Images were collated in Adobe Photoshop and color levels
were adjusted uniformly across experiments before conversion to
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